Declining Pharmaceutical Quality, Recalls, Sales Discontinuations and Claims for Damages
First written in FY2018. 9 of 12 entries say "Restated". Latest entry: FY2025.
Koa Shoji Holdings moved to the "Worse" side of this theme in 2021, 4 years before the typical company in this theme (2025).
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「If, with respect to pharmaceuticals for which the Group supplies active pharmaceutical ingredients, conducts development and manufacturing, or provides contract manufacturing, sales discontinuations, product recalls, damages or other events arising from these circumstances occur beyond the scope of its quality assurance efforts, the Group's operating results and financial position may be affected.」
The company continues to describe the risks of declining quality, recalls, sales discontinuations and damages relating to active pharmaceutical ingredients, development and manufacturing, and contract manufacturing. - FY2024-Q3RestatedAnnual report
「Stable supply is a prerequisite for promoting the use of generic drugs.」
The company reconfirms its recognition that quality and stable supply of generic drugs are prerequisites for market expansion. - FY2024-Q2RestatedAnnual report
「In the pharmaceutical industry, supply uncertainty continues throughout the generic drug sector, but」
The company reconfirms its recognition that supply uncertainty continues throughout the generic drug industry. - FY2024-Q1RestatedAnnual report
「In the pharmaceutical industry, supply uncertainty continues throughout the generic drug sector, but」
The company reconfirms its recognition that supply uncertainty continues in connection with quality problems in the generic drug industry caused by violations of the Pharmaceuticals and Medical Devices Act. - FY2023-Q2RestatedAnnual report
「Meanwhile, quality-related problems caused by violations of the Pharmaceuticals and Medical Devices Act have led to supply uncertainty throughout the generic drug industry, making it necessary to ensure confidence in quality and stable supply.」
The company continues to describe quality problems and supply uncertainty across the generic drug industry resulting from violations of the Pharmaceuticals and Medical Devices Act, as well as the need to ensure reliability. - FY2023-Q1RestatedAnnual report
「Meanwhile, quality-related problems caused by violations of the Pharmaceuticals and Medical Devices Act have led to supply uncertainty throughout the generic drug industry, making it necessary to ensure confidence in quality and stable supply.」
The company continues to describe quality problems and supply uncertainty in the generic drug industry, as well as the need to ensure confidence in quality and stable supply. - FY2022-Q3RestatedAnnual report
「Supply uncertainty has arisen across the generic drug industry as a result of a series of serious quality problems caused by violations of the Pharmaceuticals and Medical Devices Act, and ensuring the reliability of generic drug quality and stable supply is required.」
Without attributing the issue to a quality incident specific to the company, the company continues to describe serious quality problems and supply uncertainty across the generic drug industry, as well as the need to ensure reliability. - FY2022-Q2MaterialisedAnnual report
「In recent years, supply uncertainty has arisen as a series of serious quality problems caused by violations of the Pharmaceuticals and Medical Devices Act have occurred throughout the generic drug industry.」
Without attributing the issue to a quality incident specific to the company, the company states that serious quality problems caused by violations of the Pharmaceuticals and Medical Devices Act and supply uncertainty have actually arisen across the generic drug industry. The income statement also includes ¥34.953 million in costs related to voluntary recalls. - FY2022-Q1RestatedAnnual report
「In recent years, a series of serious quality-related problems have occurred in the generic drug industry.」
The company continues to state that a series of serious quality problems have occurred in the generic drug industry. - FY2021WorsenedAnnual report
「Last year, quality problems including health hazards and product recalls came to light, and the generic drug industry as a whole is working to restore confidence, including by reviewing its quality-control systems.」
Without attributing the issue to a quality incident specific to the company, the company describes the emergence of quality problems, including health hazards and product recalls, across the generic drug industry as a deterioration in the quality-risk environment. - FY2019RestatedAnnual report
「If, with respect to pharmaceuticals for which the Group supplies active pharmaceutical ingredients, conducts development and manufacturing, or provides contract manufacturing, sales discontinuations, product recalls, damages or other events arising from these circumstances occur beyond the scope of its quality assurance efforts, the Group's operating results and financial position may be affected.」
The company continues to describe the possibility of declining pharmaceutical quality, recalls, sales discontinuations and damages. - FY2018First statedAnnual report
「If sales discontinuations, product recalls, damages or other events arising from these circumstances occur beyond the scope of the Group's quality assurance efforts, the Group's operating results and financial position may be affected.」
Quality risks including adverse effects, foreign matter contamination, re-examination and re-evaluation, and recalls of overseas active pharmaceutical ingredient lots.